ABBV Stock Overview
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. More details
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 4/6 |
Past Performance | 1/6 |
Financial Health | 3/6 |
Dividends | 4/6 |
Community Narratives
Narratives bring a range of perspectives from our community.
AbbVie Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$176.46 |
52 Week High | US$207.32 |
52 Week Low | US$144.73 |
Beta | 0.56 |
11 Month Change | -11.98% |
3 Month Change | -8.50% |
1 Year Change | 20.55% |
33 Year Change | 44.79% |
5 Year Change | 103.53% |
Change since IPO | 404.17% |
Recent News & Updates
AbbVie: Upgrading To 'Strong Buy' After Pullback
Nov 22AbbVie's (NYSE:ABBV) Dividend Will Be Increased To $1.64
Nov 19AbbVie's (NYSE:ABBV) Soft Earnings Are Actually Better Than They Appear
Nov 12Recent updates
AbbVie: Upgrading To 'Strong Buy' After Pullback
Nov 22AbbVie's (NYSE:ABBV) Dividend Will Be Increased To $1.64
Nov 19AbbVie's (NYSE:ABBV) Soft Earnings Are Actually Better Than They Appear
Nov 12AbbVie Stock: Keep Calm And Buy The Dip
Nov 11AbbVie: 3 Positives From The Earnings Report
Oct 30AbbVie: Strong Dividends But Humira Disappoints
Oct 22AbbVie: Dividend Discount Model Suggests Large Valuation Risks
Sep 29We Think AbbVie (NYSE:ABBV) Can Stay On Top Of Its Debt
Sep 06Why AbbVie Remains One Of My Favorite Dividend Growers
Aug 27AbbVie: Growth Is Still A Better Choice
Jul 29AbbVie Q2 2024 Earnings Preview: Post Gonzalez Era Can Begin On Positive Note
Jul 17AbbVie: A Hold Again (Rating Downgrade)
Jul 03Earnings Tell The Story For AbbVie Inc. (NYSE:ABBV)
Jun 28AbbVie: 5 Reasons That Make A Buy Case
Jun 18Looking For Both Income And Growth? 4%-Yielding AbbVie Has You Covered
May 29Shareholder Returns
ABBV | US Biotechs | US Market | |
---|---|---|---|
7D | -3.6% | -0.8% | 0.4% |
1Y | 20.5% | 12.9% | 32.3% |
Return vs Industry: ABBV exceeded the US Biotechs industry which returned 12.9% over the past year.
Return vs Market: ABBV underperformed the US Market which returned 32.3% over the past year.
Price Volatility
ABBV volatility | |
---|---|
ABBV Average Weekly Movement | 4.7% |
Biotechs Industry Average Movement | 10.0% |
Market Average Movement | 6.3% |
10% most volatile stocks in US Market | 16.3% |
10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ABBV has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: ABBV's weekly volatility (5%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2012 | 50,000 | Robert Michael | www.abbvie.com |
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn’s disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine.
AbbVie Inc. Fundamentals Summary
ABBV fundamental statistics | |
---|---|
Market cap | US$320.74b |
Earnings (TTM) | US$5.08b |
Revenue (TTM) | US$55.53b |
61.4x
P/E Ratio5.6x
P/S RatioIs ABBV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
ABBV income statement (TTM) | |
---|---|
Revenue | US$55.53b |
Cost of Revenue | US$16.47b |
Gross Profit | US$39.06b |
Other Expenses | US$33.98b |
Earnings | US$5.08b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 2.88 |
Gross Margin | 70.33% |
Net Profit Margin | 9.15% |
Debt/Equity Ratio | 1,174.8% |
How did ABBV perform over the long term?
See historical performance and comparisonDividends
3.7%
Current Dividend Yield216%
Payout RatioDoes ABBV pay a reliable dividends?
See ABBV dividend history and benchmarksAbbVie dividend dates | |
---|---|
Ex Dividend Date | Jan 15 2025 |
Dividend Pay Date | Feb 14 2025 |
Days until Ex dividend | 41 days |
Days until Dividend pay date | 71 days |
Does ABBV pay a reliable dividends?
See ABBV dividend history and benchmarks